The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Iguratimod May Hold Promise for Treating Autoimmune Disease

Iguratimod May Hold Promise for Treating Autoimmune Disease

October 22, 2019

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say.

You Might Also Like
  • T Cell Exhaustion: A New Strategy for Treating Autoimmune Disease
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis
  • Immunotherapy Largely Untested in Patients with Autoimmune Disease

Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on bone metabolism, the team notes in Bone Research, online Sept. 3, where they review the various effects of the drug.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Iguratimod was approved in China in 2011 and Japan in 2012, and most studies have described its use in patients with RA, according to Dr. Qiang Shu from Qilu Hospital of Shandong University, Ji’nan, and Shenzhen Research Institute of Shandong University, Shenzhen, and colleagues.

One report indicated that iguratimod is more efficient than other current anti-rheumatic drugs against TNF-alpha, IL-4, IL-6, NF-kappaB and IL-17, key players in the inflammatory cascade.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Iguratimod has also shown promise in other inflammatory diseases (e.g., axial spondyloarthritis and pulmonary fibrosis) and autoimmune diseases (e.g., inflammatory bowel disease, Kawasaki disease and lupus nephritis), they authors say.

Bony effects of iguratimod include stimulation of osteoblast differentiation to increase bone formation and inhibition of osteoclast differentiation to diminish bone resorption. In RA, iguratimod enhances ossification and protects the bone by activating osteoclasts.

Nausea, dizziness, headache and itching have been reported in association with iguratimod use. The incidence of adverse effects seems to be similar for iguratimod and methotrexate.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We suggest that iguratimod’s unique mode of action compared with that of other disease-modifying anti-rheumatic drugs and its good patient response makes it a suitable anti-rheumatic and bone-protecting drug,” the authors conclude.

Dr. Shu did not respond to a request for comments.


Reference

  1. Li J, Zeng J, Yan A, et al. Iguratimod: A valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. Bone Research. 2019 Sep 3; 7:27.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Autoimmune disease, bone, China, iguratimod

You Might Also Like:
  • T Cell Exhaustion: A New Strategy for Treating Autoimmune Disease
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis
  • Immunotherapy Largely Untested in Patients with Autoimmune Disease
  • Adalimumab Appears Safe for Treating Pediatric Patients with Autoimmune Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)